Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

41.94 -2.91 (-6.49%)
Streaming Delayed Price Updated: 12:15 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
News headline image
Sanofi Q2 Earnings Call Highlights ↗
Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also... 
Via MarketBeat
Topics Earnings
News headline image
The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗
Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗
Via Chartmill
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗
Via Chartmill
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals ↗
Via Chartmill
SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals ↗
Via Chartmill
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals ↗
Via Chartmill
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
All three can be bought on the dip. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗
These stocks pay between 5.3% and 6.7% in dividends. 
Via The Motley Fool
Topics Intellectual Property
Sanofi (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals and a 5.26% Payout ↗
Via Chartmill
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
The stock looks cheap, but appearances can be deceiving. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
News headline image
1 Dirt Cheap Growth Stock to Buy Right Now ↗
Sanofi is generating some solid growth and it trades at an incredibly low valuation. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
Is This Biotech Stock a Buy After a Groundbreaking Approval? ↗
This milestone came with an asterisk. 
Via The Motley Fool
News headline image
Recursion (RXRX) Q1 2026 Earnings Transcript ↗
Recursion (RXRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past. 
Via The Motley Fool
News headline image
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10% ↗
Via MarketBeat
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
It will be a turbulent ride, but patient investors might come out of it much richer. 
Via The Motley Fool
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff... 
Via MarketMinute
Topics Economy Government Lawsuit
News headline image
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines... 
Via MarketMinute
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.